Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,003

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 14, 2019

Study Completion Date

May 14, 2019

Conditions
HIV
Interventions
DRUG

LPV/RTV pellets and AZT/3TC or ABC/3TC

"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day"

Trial Locations (11)

Unknown

AMPATH - Moi Teaching and Referral Hospital, Eldoret

FACES Lumumba Clinic, Kisumu

Gertrude's Children Hospital, Nairobi

Kenyatta National Hospital, Nairobi

Management and Development for Health(MDH) , at Temeke and Amana Hospitals, Dar es Salaam

Ifakara health Institute, Morogoro

Joint Clinical research Centre, Fort Portal

Joint Clinical Research Centre, Gulu

Baylor College of Medicine, Children's Foundation - Uganda, Kampala

Joint Clinical research Centre, Kampala

Epicentre Mbarara Research Centre, Mbarara

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

UNITAID

OTHER

collaborator

French Development Agency

OTHER_GOV

lead

Drugs for Neglected Diseases

OTHER